Rocatinlimab met its Phase III endpoints with results that appear uncompetitive with AD market leader Dupixent, while Uplizna may offer a compelling twice-yearly gMG treatment option.

Halozyme’s Enhanze technology has now brought seven monoclonal antibodies, including Ocrevus and Tecentriq, from IV to subcutaneous delivery, but Alteogen and other high-concentration formulation players hope to join the party as Medicare pricing issues help drive interest.

Deals in pharma to secure market access are now business as usual. More deals will be needed in future too. Yet they take time and are not easy to successfully conclude. Could nudging the negotiations help?

Being the Chinese biotech’s backbone asset in the autoimmune disease area, telitacicept, a BlyS/APRIL dual targeting fusion protein, has hit its target in a China-only Phase III study in generalized myasthenia gravis. The candidate is also being investigated in global Phase III trials in systemic lupus erythematosus and Sjögren's syndrome.